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Liposomes modulate human immunodeficiency virus infectivity
Krystyna Konopka, 1 Brian R. Davis, 3 Charles E. Larsen,11 " Dennis R. Alford,11" Robert J. Debs 1
and Nejat Diizgiine~ 1, 2,
1Cancer Research Institute and 2Department o f Pharmaceutical Chemistry, University o f California, San Francisco,
California 94143-0128 and 3Medical Research Institute of San Francisco at Pacific Presbyterian Medical Center,
San Francisco, California 94115, U.S.A.

We have investigated the effects of the fusion of
liposomes with human immunodeficiency virus type 1
( H I V - 1 L V A ) o n the ability of the virus to infect CD4 ÷
and CD4- cells. Fluorescence dequenching measurements indicated that HIV-1 fuses with liposomes
composed of either cardiolipin (CL) or N-[2,3-(dioleyloxy) propyl]-N,N,N-trimethyl ammonium chloride
(DOTMA) but not appreciably with dioleoylphosphatidylcholine (DOPC) liposomes. Pre-incubation of
HIV-1 with DOTMA liposomes enhanced virus production (measured by p24 gag antigen production in
the culture medium and in situ) in CD4 ÷ A3.01 and H9
cells in a concentration-dependent manner, but did not
mediate the infection of the CD4- cell line, K562. Pre-

incubation of HIV-1 with between 10 and 30 ~tMD O T M A liposomes, and subsequent incubation with
A3.01 cells, resulted in the production of about 30-fold
greater levels of virus than controls. The presence of
D O T M A liposomes during the incubation of A3.01
cells with HIV-1 enhanced the infectivity of the virus
up to 90-fold compared to controls. Conversely, preincubation of HIV-1 with CL liposomes inhibited
infection of A3.01 cells, dependent on the concentration of liposomes; DOPC liposomes did not alter the
infectivity of the virus under any of the incubation
conditions. Our results thus indicate that fusion of
HIV-1 with liposomes alters the ability of the virus to
infect its target cells.

Introduction

liposomes. Here, we have investigated whether the
products of the fusion of HIV-1 with CL liposomes alter
the infectivity of the virus. We have also investigated the
fusion of HIV-1 with liposomes composed of the
positively charged synthetic lipid N-[2,3-(dioleyloxy)
propyl]-N,N,N-trimethyl
ammonium
chloride
(DOTMA) and the infectivity of the fusion product. We
have found that DOTMA liposomes enhance the
infectivity of the virus and CL liposomes inhibit it,
whereas DOPC liposomes (which do not fuse appreciably with HIV-1) are ineffective.

Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4 ÷ T lymphocytes, monocytes and macrophages (Dalgleish et al., 1984; Klatzmann et al., 1984;
Gartner et al., 1986; Ho et al., 1986; McDougal et al.,
1986). Recent studies have shown, however, that cells
that do not express CD4 can also be infected with HIV
(Cheng-Mayer et al., 1987; Clapham et al., 1989;
Harouse et al., 1989; Tateno et al., 1989). Furthermore,
expression of the CD4 molecule on the cell surface may
not be sufficient for HIV-1 infection (Maddon et al.,
1986; Chesebro et al., 1990); fusion of HIV-1 with the
target cell membrane appears necessary for productive
infection. We have reported recently that HIV-1 and
simian immunodeficiency virus (SIVmac) can fuse with
liposomes (phospholipid vesicles) that do not contain the
CD4 molecule (Larsen et al., 1989, 1990). SIVma c fuses
rapidly, at neutral pH, with negatively charged liposomes composed of cardiolipin (CL), CL and dioleoylphosphatidylcholine (DOPC) (3 : 7), or phosphatidylserine. We have also reported that HIV-1 fuses with CL
t Present address: Department of Bioscience and Biotechnology,
Drexel University, Philadelphia, Pennsylvania 19104, U.S.A.
0000-9666 © 1990 SGM

Methods
Chemicals. DOPC and CL from bovine heart were obtained from
Avanti Polar Lipids and stored in chloroform under argon in sealed
ampoules at - 7 0 °C. DOTMA, synthesized as described previously
(Feigner & Ringold, 1989) and kindly provided by N. Dyson at Syntex
Research, was stored in ethanol under argon at - 70 °C. Octadecylrhodamine (Rls) was purchased from Molecular Probes and C12Es
detergent was from Calbiochem.
Cell lines. The cell lines A3.01, H9 and K562 were used for our
studies. The chronically infected cells, H9/human T-cell lymphotropic
virus type III (HTLV-IIIB), were used as a positive control for the
determination of viral p24 antigen inside the cells. The CD4 ÷ human
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lymphoblastoid cell line A3.01 was obtained from T. M. Folks (Centers
for Disease Control,Atlanta, Ga., U.S.A.). The following cell lines were
obtained through the AIDS Research and Reference Reagent Program
NIAID: H9 cells from R. C. Gallo; the H9/HTLV-III Bcell clone from
L. Arthur. The CD4- human chronic myelogenous leukaemia cell line,
K562, was obtained from the American Type Culture Collection. Cells
were cultured at 37 °C (7~ CO2). The A3.01, K562 and H9/HTLVIIIa cell lines were propagated in RPMI 1640 medium supplemented
with 10~ (v/v) heat-inactivated foetal bovine serum (FBS), penicillin
(50 units/ml), streptomycin (50 gg/ml) and L-glutamine (2 m~l). H9
cells were maintained in Iscove's modified Dulbecco's medium with
20~ FBS and antibiotics.

Virus. The virus and infected cell lines were handled in P-2 and P-3
facilities as recommended by the Centers for Disease Control (1988).
For fusion experiments, HIV-I (LAV, obtained from the Pasteur
Institute), propagated in human lymphoblastic leukaemia (CEM) cells,
was provided by M. Jennings (University of ralifornia, Davis, Ca.,
U.S.A.). The virus preparation and the er" . line tested negative for
Mycoplasma contamination. Cell-free medium from HIV-l-infected
cell cultures was collected and the virus was pelleted by centrifugation
and purified by sucrose density gradient centrifugation. The virus band
was collected, assayed for protein (Bradford, 1976), diluted and stored
at - 7 0 °C. A standard laboratory strain of HIV-1LAv was originally
provided by T. M. Folks and was propagated in A3.01 cells. Virus
supernatant was harvested at times of peak reverse transcriptase
activity, divided into aliquots and stored at - 8 0 °C. The reverse
transcriptase activity of the virus stock was 5.1 x 105 c.p.m./ml
supernatant, as detected by the method of Hoffman et al. (1985). The
ELISA-reactive p24 protein in the viral supernatant was present at a
concentration of approximately 1.0 ~tg/ml. Viral inocula were standardized by their content of p24 antigen and cultures were infected with 1.0
or 2.0 ng of viral p24/106 cells in all experiments.
Virus labelling. A fluorescence assay was used to monitor the
intermixing of viral and target membranes during fusion, using R18 as
the fluorescent lipid marker (Hoekstra et al., 1984; Loyter et al., 1988).
HIV-1 (100 ~tg) was labelled with a solution of Rts (final ethanol
concentration less than 1~) for 0.5 to 1 h at room temperature.
Previously reported HIV-1 lipid-to-protein ratios (Aloia et al., 1988)
were assumed for determining the amount of R~8 with which to label
the virus. The final concentration of label was 3 m o l ~ of viral lipid.
Free fluorophore was not present after labelling. An excess of
unlabelled virus did not result in redistribution of R is as measured by
fluorescence dequenching (data not shown). In some experiments, the
labelled virus was subjected to chromatography on Sephadex G-75 to
eliminate any free dye, producing a lower yield of labelled virus; the
fusion results obtained with this virus preparation were similar to those
obtained with the virus that was not subjected to chromatography.
Preparation o f liposomes. Large unilamellar vesicles composed of
DOPC or CL were prepared in 150 mM-NaCI, 10 mM-TES (Sigma and
Calbiochem) and 10 mM-citrate pH 7-5 ('fusion buffer') by a
modification (Diizgfne~ et al., 1983) of the reverse-phase evaporation
procedure (Szoka et al., 1980). Vesicles were extruded three times under
argon through double polycarbonate membranes of 0-1 ~tm pore
diameter (Poretics) in a Lipex Biomembranes high pressure extrusion
cell to achieve a uniform size distribution of vesicles (Szoka et al.,
1980). DOTMA :cholesterol (3:1) liposomes were prepared in fusion
buffer by hydrating dried lipid (Bangham et al., 1965) and extruded
three times under argon through double polycarbonate membranes (0.4
~tm pore diameter; Nuclepore). This procedure results in the
production of unilamellar vesicles (Diizgiine~ et al., 1983; Hope et al.,
1985). Pure DOTMA liposomes were prepared similarly, except that
they were extruded through membranes of 0.2 ~tm pore diameter. The

lipid concentration of phospholipids was determined by phosphate
assay (Bartlett, 1959).

Fusion experiments. The dilution of R18 into the target membranes
was measured by following the increase of rhodamine fluorescence,
which results from the relief of self-quenching upon membrane fusion
(Hoekstra et aL, 1984). Fluorescence measurements were performed
with a Perkin-Elmer LS-5B fluorimeter, linked through a MacAdios
analog :digital converter using Manager II software (GW Instruments), to a Macintosh SE/30 computer to collect raw data. The
excitation wavelength was 555 nm and the emission monochromator
was set at 595 nm, with a 590 nm high-pass cut-off filter. All
experiments were performed at 37 °C in a stirred cuvette. Liposomes
were rapidly injected into a temperature-equilibrated cuvette containing labelled virus in fusion buffer set to pH 7.5. The final reaction
volume was 2-0 ml. The fluorescence scale was calibrated to 100%
(complete dilution of the probe; i.e. complete fusion) by addition of 0.1
to 0-5% (final concentration) of C~2E8 detergent to disperse the R18
completely. All data were collected within 6 months of virus
preparation.
Detection of CD4. The presence of cell surface CD4 protein was
examined by direct immunofluorescence assay, using fluorescein
isothiocyanate (FITC)-conjugated Leu3 antibody (Becton-Dickinson)
with FITC-conjugated mouse IgG as a control. The fluorescence
distribution was analysed with a fluorescence-activated cell sorter
(FACScan; Becton-Dickinson).
HIVinfection o f cells. Cells (2 x 107/ml) were incubated with HIV-1
for 2 h at 37 °C to permit adsorption of virus particles and then washed
three times to remove unbound virus. Cells were then resuspended at
5 x 105 cells/ml in RPMI 1640/10% FBS or Iscove's modified
Dulbecco's medium/20% FBS and cultured at 37 °C in 48-well culture
plates (0.6 ml per well), or in 25 cm 2 culture flasks, and maintained in 10
ml of medium. Control cells were similarly treated but not exposed to
the virus. Samples (400 ~tl)of the supernatant were collected every 3 or 4
days for subsequent screening by ELISA for HIV p24 antigen content;
400 ktl of fresh medium was added to each well. The effect of liposomes
on HIV infectivity was investigated by three different protocols: (i) the
virus was pretreated with liposomes before addition to the cells, (ii)
liposomes were added to the culture medium during the exposure of
cells to virus, or (iii) liposomes were added after the cells had been
exposed to virus and washed.
HIV-1 (0-4 p.g viral p24/ml) was preincubated with various
concentrations of liposomes for 2 h at 37 °C and then diluted with a cell
suspension to give 1 or 2 ng of viral p24 protein/106 cells. After virus
adsorption for 2 h at 37 °C, the cells were washed three times,
resuspended at 5 × 105 cells/ml and cultured in 48-well culture plates.
Following incubation, the number of viable cells was determined by
trypan blue exclusion and p24 antigen was measured in duplicate in
supernatant collected independently from two or three wells.
Detection o f H I V infection. H/V-specific antigens were detected in
cell culture supernatants using an HIV-1 p24 antigen capture assay.
The expression of HIV antigen in the infected and mock-infected cells
was determined using a mouse anti-p24 monoclonal antibody and
soluble complexes of calf intestinal alkaline phosphatase and mouse
anti-alkaline phosphatase monoclonal antibodies (APAAP; Dako).
After the cells were washed with phosphate-buffered saline (PBS;
Zymed Laboratories), they were suspended in PBS, placed on 10-well
slides and fixed for between 3 and 5 min in acetone. The slides were
overlaid with a mouse monoclonal antibody to HIV-1 p24 protein,
rabbit anti-mouse immunoglobulins and APAAP and stained using the
Alkaline Substrate Kit (Vector Laboratories). The uninfected cells and
H9/HTLV-III B cells were used as negative and positive controls,
respectively.

Modulation o f H I V infectivity by liposomes
p24 antigen captureassay. Cell-freesupernatant fluids were assayed in
duplicate by an HIV-1 p24 antigen capture assay with two mouse
monoclonal antibodies specific for the HIV p24 gag protein,
recognizing different epitopes. ELISA plates (96-well; Coming) were
coated overnight with the capture antibody, incubated with 0-1%
bovine serum albumin in PBS for 1 h at room temperature and washed
three times with PBS-Tween 20 (0.05%). Next, supernatant (100 Ixl)
was added and samples were incubated for 2 h at 37°C. The
biotinylated detector antibody was subsequently added and after 1 h
incubation at 37 °C the antibody was bound with avidin-horseradish
peroxidase. Colour develops from the reaction of the peroxidase with
hydrogen peroxide in the presence of o-phenylene diamine (Dakoparts); the absorbance was read at 490 nm. The p24 antigen was
quantified from serial dilutions of a positive control preparation
containing a known amount of antigen. A culture supernatant
containing a known amount of p24, calibrated with the lyophilized
Antigen Reagent (Coulter HIV Ag Assay) (Coulter Immunology),was
used as a standard. The sensitivity of detection was routinely 38 pg
p24/ml of cell culture supernatant.
Detection of HIV DNA sequences by the polymerase chain reaction
(PCR). K562 cells (either uninfected or exposed to HIV-1 preincubated
in the presence or absence of 10 IxM-DOTMA liposomes) were
maintained as described above. After 3 and 10 days of culture, K562
ceils at a density of 5 x 106/ml were treated for 1 h at 56°C in
1 × amplification buffer (50 mM-KCI,10 mM-Tris-HC1pH 8.3, 2.5 mMMgClz, 0-1 mg/ml gelatin) containing 0-45% NP40, 0-45% Tween 20
and 60 ~g/ml proteinase K ; proteinase K was subsequently inactivated
at 100 °C for 10 rain. Aliquots of lysate containing 105 cell equivalents
were amplified for 35 cycles using HIV env primers SK68/69,
essentially according to Ou et al. (1988). Detection of env-specific
amplified sequences was performed by liquid hybridization with a 32p_
labelled internal probe (SK70) (Ou et al., 1988), polyacrylamide gel
electrophoresis and autoradiography. The reactions were performed
together with negative-DNA samples, as a control for carryover, and
with a dilution series of HIV-infected cells (8E5 cells, one HIV proviral
DNA copy per cell) (Folks et aL, 1986) to enable quantification of HIV
DNA sequences present in a given sample.

Blocking experiments. A3.01 cells (2 × 107 cells/ml) were preincubated with the anti-CD4 antibody Leu3a at a concentration of 10 ktg/ml
for 1 h at 37 °C (Weber et aL, 1989). Leu3a antibody has been shown to
block HIV infection of T cells (Sattentau et al., 1986). The cells preincubated with anti-Leu3a and untreated cells were then exposed to
HIV-I at 1ng viral p24/106 cells for 2 h at 37 °C, in the presence of 5 ~tMDOTMA or in the absence of liposomes. The cells were then washed
three times and cultured for 7 days.
Statistical comparisons were performed using a Student two-sided
unpaired t-test.

Results
Fusion o f H I V - 1 with liposomes is dependent on
membrane composition
F u s i o n of HIV-1 with liposomes at n e u t r a l p H was
d e p e n d e n t on the lipid c o m p o s i t i o n o f the liposomes
(Fig. 1). F u s i o n was fastest a n d most extensive with
liposomes composed of D O T M A : c h o l e s t e r o l (3:1).
F u s i o n of the virus with C L liposomes, although fairly
d r a m a t i c , was s o m e w h a t slower t h a n with D O T M A :
cholesterol (3:1) liposomes. T h e virus did n o t fuse
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Fig. 1. Kinetics of fusion between HIV-I and liposomes of various
composition. Fusion between R~s-labelled HIV-1 (1 lag/ml) and
liposomes (50 ~tM-lipid)(which corresponds to an approximate 100:1
liposome : virus lipid ratio) was monitored continuouslyat pH 7.5 as the
increase of Rls fluorescence due to lipid mixing.

a p p r e c i a b l y with pure D O P C m e m b r a n e s , with only 3 %
fluorescence d e q u e n c h i n g after 4 m i n i n c u b a t i o n .

Treatment with cationic D O T M A liposomes enhances the
replication o f H I V in A 3 . 0 1 cells
T h e C D 4 molecule f u n c t i o n s as a receptor for the H I V
envelope glycoprotein g p l 2 0 (Dalgleish et al., 1984;
K l a t z m a n n et al., 1984) a n d the susceptibility of the cells
to H I V infection is associated with the expression of
C D 4 o n their surface (Sodroski et al., 1986). F A C S
analysis indicated that 9 0 ~ of the A 3 . 0 1 cells used in our
studies were C D 4 ÷ (data n o t shown). To d e t e r m i n e the
effect of the c o n c e n t r a t i o n of D O T M A liposomes on
HIV-1 infectivity, virus was p r e i n c u b a t e d with v a r y i n g
c o n c e n t r a t i o n s of D O T M A liposomes (0.1 to 50 ~tMlipid). T h e m i x t u r e was t h e n diluted a n d i n c u b a t e d with
A3.01 cells for 2 h a n d the cells were cultured for 7 days.
This t r e a t m e n t e n h a n c e d virus infectivity over a b r o a d
range of liposome c o n c e n t r a t i o n s , with a n o p t i m u m
b e t w e e n 10 a n d 30 ~tM-lipid (Fig. 2). I n this c o n c e n t r a t i o n
range, virus infectivity was e n h a n c e d by a b o u t 30-fold.
I n f e c t i o n was also followed by i m m u n o h i s t o c h e m i c a l
s t a i n i n g ( A P A A P assay) of infected a n d m o c k - i n f e c t e d
cells. T h e expression of p24 a n t i g e n in H I V - l - i n f e c t e d
cells correlated well with the level of p r o d u c t i o n of p24
a n t i g e n , d e t e r m i n e d in the s u p e r n a t a n t (data n o t shown).
Despite the increased p r o d u c t i o n of p24 protein, no loss
of cellular viability was noted.
To study the kinetics of viral replication, A 3 . 0 1 cells
were infected with HIV-1 p r e i n c u b a t e d with 10 ~tMD O T M A liposomes or with u n t r e a t e d virus. T h e
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Fig. 2. Effect of preincubation of HIV-1 with various concentrations
of DOTMA liposomes (0.1 to 50 ktu-lipid) on HIV-1 replication in
A3.01 cells, p24 antigen was detected in the cell culture supernatant 7
days p.i. Data represent mean values ___s.o. (n = 4).
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Fig. 4. Effect of the time of the addition of DOTMA liposomes on
HIV-1 replication in A3.01 cells. 1. HIV-1 was preincubated with
DOTMA liposomes (5 gM-lipid) for 2 h at 37 °C before infection of the
cells (1 ng viral p24/1 x 106 cells). 2. Cells were incubated with HIV-1
in the presence of 5 P-M-DOTMAfor 2 h, then washed and maintained
as above. 3. Cells were infected with HIV-1, then washed and
resuspended in medium containing 5 pM-DOTMA at 5 x 105 cells/ml.
Samples (400 p.1)of the culture supernatant were removed 3 days p.i.
and fresh medium with 5 gM-DOTMA was added to each well. 4. Cells
were infected with HIV-I and cultured in the absence of DOTMA. In
all cases, p24 antigen was detected in cell culture supernatant on day 7
p.i. Data represent mean values + S.D, (n = 6).
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Fig. 3. Kinetics ofp24 antigen production in the culture supernatantof
A3.01 cells infected with HIV-1 preincubated with DOTMA liposomes (10 gM-lipid)(O), or with untreated virus (©). Supernatants were
collected on 3, 7,10 and 13 days p.i. and assayed for p24 antigen. Data
represent mean values (n = 6).

infectivity o f the virus preincubated with D O T M A
liposomes was strongly increased; p24 appeared in the
supernatant 3 days post-infection (p.i.) (Fig. 3) and
reached a p e a k value o f approximately 2 gg p24/ml after
10 days of culture (Fig. 3, inset). In contrast, w h e n A3.01
cells were infected with untreated HIV-1, the production
o f p24 was not detectable before 7 days p.i. and, by 10
days, reached only 2 - 2 ~ of the value obtained by
inoculation with D O T M A - p r e t r e a t e d virus (Fig. 3,
inset).
The stimulatory effect of D O T M A liposomes on H I V 1 infection o f A3.01 cells was dependent on the time of
addition o f D O T M A . W h e n 5 p.M-DOTMA liposomes

were present during infection, HIV-1 replication was
increased by about 10-fold c o m p a r e d to cells exposed to
HI'q-1 preincubated with the same concentration o f
D O T M A (Fig. 4). This a m o u n t s to a 90-fold enhancem e n t o f infectivity c o m p a r e d to untreated HIV-1. A3.01
cells incubated with untreated virus and then cultured in
the presence o f 5 ~tM-DOTMA liposomes showed a small
but statistically significant (P < 0-0005) increase in p24
antigen production from 2.63 + 0.45 to 5.41 + 0.55 ng/ml
observed on day 7 p.i. (Fig. 4). T h e presence o f 5 ~tMD O T M A in the culture m e d i u m for 7 days following
infection did not affect the viability o f A 3 . 0 1 cells.

Effect of DO TMA liposomes on H I V infection of H9 and
K562 cells
E n h a n c e m e n t o f HIV-1 infection by D O T M A liposomes
was also tested in another C D 4 + cell line, H9. O f these
cells, 5 2 ~ were C D 4 + (data not shown). T h e effect of
D O T M A liposomes was determined under three experimental conditions: H9 cells were incubated either with
HIV-1 preincubated with 5 ~tM-DOTMA, or with HIV-1
in the presence o f D O T M A liposomes; alternatively,
cells inoculated with untreated virus were cultured in the
presence o f 5 ~tM-DOTMA liposomes for 3 days and then
cultured in the absence o f liposomes (Table 1). The
results indicate that the first two conditions e n h a n c e d
viral infectivity to a similar extent. A fivefold enhance-

Modulation of HIV infectivity by liposomes
Table 1. Effect of DOTMA liposomes on HIV-1 replication
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in H9 cells
Treatment
Time
DOTMAp.i. pretreated HIV
(days)
+ H9 cells
7
10
14

2.6+0.4*
6.5 + 0.9
388.0 + 67.8

DOTMA
+ H9 cells
+ HIV

300

Infected
H9 cells
+ DOTMA

H9 cells
+ HIV
(control)

1.2+0.1
0.5+0.15
5-3 + 1.2
2.3 + 0-6
377.0 + 90.2 201.5+ 77.3

0.5+0.2
1.2 + 0-2
71-5 + 20-9

200
m~

100

* p24 Antigen was determined in cell culture supernatants on 7, 10
and 14 days p.i. Data represent mean p24 ng/ml + S.D. (n = 6).
0 ~

1

ment of p24 production was observed after 10 and 14
days when compared to H9 cells infected in the absence
of D O T M A (Table 1). By comparison, the presence of
D O T M A liposomes during the adsorption of virus to
A3.01 cells resulted in a much higher stimulation of
infection, with a 90-fold enhancement of p24 production
7 days p.i. (Fig. 4). Addition of 5 ~tM-DOTMA liposomes
to A3.01 or H9 cells previously infected with HIV-1
resulted in a similar enhancement of p24 production
(approximately twofold compared to untreated controls;
Fig. 4 and Table 1).
C D 4 - K562 cells were not susceptible to infection by
either D O T M A - p r e t r e a t e d or untreated virus (2 ng viral
p24/106 cells), as determined by the absence of p24 in the
cell culture supernatant (data not shown). We have been
able to detect by P C R amplification a very low amount
of H I V proviral D N A (between 2 and 10 copies per 105
cells) in K562 cells, infected either with untreated HIV-1
or with HIV-1 pretreated with 10 ~tM-DOTMA liposomes, incubated for 3 days following the 2 h infection
period; HIV-1 D N A was not detectable on day 10 p.i.
(data not shown). At the present time we are not able to
distinguish whether this low level H I V D N A represents
newly synthesized H I V proviral D N A (by reverse
transcription) or contaminating viral D N A from infected cells in the virus inoculum. The level of H I V proviral
D N A was not increased after exposure of K562 cells to
D O T M A - p r e t r e a t e d HIV-1, indicating that the presence
of D O T M A liposomes did not enhance HIV-1 infection
and replication in C D 4 - K562 cells.

Anti-Leu3a antibody inhibits the enhancement of HIV-1
infectivity by DOTMA liposomes
To ascertain whether the enhancement of HIV-1
infectivity by D O T M A liposomes required the CD4
receptor, we used anti-Leu3a antibodies that recognize
the epitope on CD4 involved in binding to the H I V

2

3

4

Fig. 5. Effect of the anti-CD4 antibody, anti-Leu3a, on HIV-1
infection of A3.01 ceils in the presence and absence of DOTMA
liposomes. Cells were preincubated with anti-Leu3a (1 and 2) and then
exposed to HIV-1 as described in Methods. 1. HIV-1 was added in the
presence of antibody and 5 ~tM-DOTMA liposomes. 2. HIV-1 was
added in the presence of antibody. 3. HIV-1 was added in the absence
of antibody and the presence of 5 IxM-DOTMAliposomes. 4. HIV-1
alone was added, p24 antigen was detected in the cell culture
supernatant 7 days p.i. Data represent mean values + S.D.(n = 4). The
S.D. values for 1 and 4 are too small to be shown at this scale, and are
given in the text.

envelope glycoprotein, gp120 (Sattentau et al., 1986).
HIV-l-infected A3.01 cells produced 3.07 + 0.22 ng/ml
p24 in 7 days (Fig. 5). Preincubation of A3.01 cells with
Leu3a antibody completely abolished the infectivity of
HIV-1 (bar 2 in Fig. 5). When HIV-1 was added to Leu3a
antibody-pretreated cells in the presence of D O T M A
liposomes, the amount of p24 produced by these cells was
reduced to 7~o (21-1 + 0.9 ng/ml) of the value produced
by cells infected with HIV-1 in the presence of liposomes
without antibody pretreatment (319 + 56 ng/ml).

Anti-HIV activity of CL liposomes
It was of interest to examine whether the fusion product
of HIV-1 and CL liposomes would retain the infectivity
of the virus towards CD4 + cells. The antiviral effect of
CL liposomes was evaluated in experiments in which
A3.01 cells, highly susceptible to infection, were infected
with H I V - I that had been preincubated with various
concentrations of these liposomes. The results (Table 2)
indicate that preincubation of HIV-1 with CL liposomes
resulted in a dose-dependent inhibition of virus replication. The expression of p24 protein in HIV-l-infected
cells correlated well with the production of p24 determined in the supernatant (data not shown). The
concentrations of CL liposomes at which inhibition of
infectivity was observed were not toxic to the cells.

2904

K. Konopka and others

Table 2. Effect of preincubation of HIV-1 with CL
liposomes on HIV-1 replication in A3. O1 cells
p24 (ng/ml)l"
Treatment*

7 days p,i.

10 days p.i.

+ HIV (control)
10 p.M-CL
25 p.M-CL
50 ~tM-CL
75 I.tM-CL
100 IxM-CL

7-8 _ 2-1
5-7 + 1-0
3.3 ___0-9
1.7 + 1.0
0-9 + 0-5
0.03 + 0.02

813-2 _ 131-0
810-8 + 220-5
249-0 + 74-9
52.0 + 8.9
22-0 +__10.4
0-7 + 0.6

13 days p.i.
1359-0 +
1193-3 +
679.0 +
366.5 +
210.0 +
13.3 +

216.4
288.5
271.0
17.6
22-2
7.8

* HIV-1 was preincubated with CL liposomes then added to A3.01
cells (2 ng viral p24/106 cells), as described in Methods. Samples (400
~tl) were collected from three wells on 7, 10 and 13 days p.i.
t Data represent m e a n values + S.D. (n = 6).

Effect o f D O P C liposomes on HIV-1 infectivity

To confirm that the effects on HIV replication observed
after preincubation of the virus with DOTMA and CL
liposomes were due to the interaction of liposomes with
the viral membrane, experiments were performed with
DOPC liposomes. HIV-! did not fuse with DOPC
liposomes to a significant level (Fig. 1). Exposure of
A3.01 cells to DOPC-pretreated virus did not affect p24
production when compared to cells incubated with
untreated virus. When A3.01 cells were infected with
virus preincubated with 10 or 100 pM-DOPC liposomes
or with RPMI medium alone (control), the values
of p24 determined in the supernatant after 7 days
were 1.33 +0.38, 1.61 _+0.18 and 1-31 _+0.51 ng/ml
(mean _+S.D., n ----4), respectively.

Discussion
Our studies, utilizing the Ris fluorescence assay for virus
fusion, have shown that HIV-1 fuses with both negatively charged CL liposomes and positively charged
DOTMA-containing liposomes. The preferential fusion
of HIV-1 with negatively charged liposomes over
uncharged liposomes at neutral pH (CL has a net
negative charge and DOPC is neutral) was qualitatively
similar to that seen with other lipid-enveloped viruses,
including SIVmac (Larsen, et al., 1989, 1990), Sendal virus
(Klappe et al., 1986) and influenza virus (Stegmann et al.,
1985, 1989). Fusion of lipid-enveloped viruses with
liposomes containing DOTMA has not been reported
previously. In this study we examined the infectivity of
the fusion product of HIV-1 with either CL or DOTMA
liposomes and the effect of the presence of these
liposomes during incubation of HIV-1 and target cells.

We found that the infectivity of HIV-1 was significantly
enhanced by DOTMA liposomes and markedly inhibited by CL liposomes, whereas DOPC liposomes had no
effect.
Positively charged DOTMA liposomes interact spontaneously with D N A or mRNA, resulting in a liposome/
polynucleotide complex that can facilitate transfection of
a wide variety of tissue culture cells (Feigner et al., 1987;
Feigner & Ringold, 1989). In the presence of serum,
DOTMA-mediated transfection is essentially blocked,
presumably due to attachment of the DNA/lipid
complexes to serum components (Feigner & Ringold,
1989). DOTMA liposomes have also been used to deliver
DNA-binding proteins to the nucleus of cultured cells
(Debs et al., 1990). The mechanism of DOTMAmediated delivery of polynucleotides or proteins into
cells is unknown, although direct fusion with the cell
membrane has been suggested (Feigner et al., 1987;
Feigner & Ringold, 1989). Liposomes composed of
DOTMA and zwitterionic phospholipids have been
shown to fuse with negatively charged liposomes, or with
each other in the presence of multivalent anions
(Dfizgiine~ et al., 1989).
Our results demonstrate that HIV-1 infection can be
enhanced after fusion of the virus membrane with
DOTMA liposomes and imply that the fusion product
delivers a functionally active virion core into the
cytoplasm with greater effÉciency than untreated virus.
The enhancing effects of DOTMA liposomes were
greatest when the liposomes were present during the
exposure of CD4 ÷ cells to H1V-1 (infection phase), when
compared to their addition after virus inoculation
(transmission phase) (Fig. 4 and Table 1). During the
transmission period, cells infected with virus become
competent to infect other CD4 + cells by the release of
viral progeny or by cell fusion (Nara et al., 1989). The
positive charge of DOTMA appeared to be necessary for
increased virus infectivity because the enhancement
could be abolished by the presence of polyanionic
oligo(dN) or non-specific DNA (unpublished data).
Polycationic reagents such as polybrene or D E A E dextran have frequently been used to increase the
efficiency of retrovirus infection in vitro (Toyoshima &
Vogt, 1969; Cheng-Mayer et al., 1987; Chesebro &
Wehrly, 1988; Tateno et al., 1989), although variability
of effectiveness was observed when these compounds
were used with different subgroups of avian retroviruses
(Toyoshima & Vogt, 1969) or with different HIV isolates
(Chesebro & Wehrly, 1988). The polycation-mediated
enhancement is at least partially due to an increased
adsorption of virus to the cell but these compounds may
also facilitate virus penetration (Toyoshima & Vogt,
1969). The enhancing effect of polycations is due to their
multiple positive charge, because the addition of
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polyanions abolished the polycation-mediated enhancement of viral adsorption (Toyoshima & Vogt, 1969).
Effective concentrations of the polycations ranged from
2 to 25 ~tg/ml. The infectivity was potentiated when
target ceils were pretreated with polycations or exposure
to virus was performed in the presence of polycations.
Pretreatment of Rous sarcoma virus with polybrene at a
concentration of 16 ~tg/ml failed to enhance infectivity
(Toyoshima & Vogt, 1969), suggesting an absence of a
strong interaction between virus and polycations. In
contrast, preincubation of HIV-1 with DOTMA enhanced the infectivity of the virus, suggesting that
DOTMA-mediated enhancement may involve fusion in
addition to the polycation effect.
It is likely that the fusion product of HIV-1 with
DOTMA containing the surface protein, gpl20, can still
bind to CD4 and use CD4 as the receptor for cellular
entry. Our data indicate that the sensitivity of the cells to
the DOTMA-mediated enhancement correlated with the
expression of CD4 on their surface; enhancement was
most pronounced in the highly CD4 ÷ A3.01 cells and
was lower in H9 cells, whereas CD4- K562 cells were not
detectably infected. This observation contrasts with the
results of Innes et al. (1990) who recently reported that
lipofectin (a commercial preparation containing
DOTMA) did not cause any enhancement of the
infectivity of murine leukaemia virus in cells containing
the viral receptor, it mediated the infection of nonpermissive cells by murine leukaemia virus and there was
a concentration-dependent inhibition of the lipofectinmediated infectivity by serum.
Blocking of infection with Leu3a antibody has been
taken as an indication that HIV-1 entry occurs predominantly via the CD4 receptor (Sattentau et al., 1986;
Weber et al., 1989); presumably the antibody inhibits
infection by binding at or near a gpl20-binding epitope
of the CD4 molecule (McDougal et al., 1986; Sattentau et
al.,1986). Weber et al. (1989) have reported that the
infection of some brain cells by HIV-1 is not blocked by
Leu3a antibodies and have concluded that infection of
these cells does not appear to involve CD4 as the
receptor. They have suggested that a non-specific
mechanism may be involved, because higher doses of
virus were required to infect these cells, and that a
second, tow-affinity, receptor for HIV entry may be used.
Our observation that, in A3.01 cells, Leu3a antibody
blocks 93 ~ of the infectivity of HIV- 1 in the presence of
DOTMA liposomes, indicates that the enhancement of
infectivity is largely via the CD4 receptor. A small
percentage of the infection in these cells appears to
proceed independently of CD4. It is likely that some of
the fusion products of HIV-1 and DOTMA liposomes
fuse with the plasma membrane because DOTMA
liposomes appear to fuse with the plasma membrane of
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cultured cells (Feigner et al., 1987; N. Diizgfine~ & L.
Stamatatos, unpublished data) and with erythrocyte
ghost membranes (N. Diizgiine~ & J. Goldstein, unpublished data).
Infectivity of HIV-1 was inhibited by prior treatment
with CL liposomes; this may be caused by either
decreased binding or decreased fusion capacity of the
fusion product. Since preincubation of HIV-1 with CL
liposomes is even more inhibitory to infection than the
presence of CL during inoculation (data not shown), the
fusion of HIV-1 with CL liposomes may also alter the
conformation of the viral envelope protein and hence its
fusogenic capacity. Alternatively, the CL molecules that
are part of the fusion product may bind cell surface
molecules and prevent the interaction of HIV-1 with its
receptor.
Schlegel et al. (1983) have shown that vesicular
stomatitis virus infection of Veto cells can be blocked by
preincubation of the virus with phosphatidylserine
vesicles and have suggested that this phospholipid may
be a receptor for the virus. Activated peripheral blood
mononuclear cells are stained with anti-CL antibodies
(Misra et al., 1989) and, because such cells are
particularly prone to infection with HIV-1 (Gowda et al.,
1988), it is possible that HIV-1 interacts with molecules
on the cell surface that mimic CL. This hypothesis is
currently being investigated.
Our observations with CL liposomes raise the possibility of using such liposomes for therapeutic purposes.
Doxorubicin-loaded CL-containing liposomes are already in phase II clinical trials for cancer chemotherapy
(Treat et al., 1989) and liposomes with prolonged
circulation times have been developed recently (Gabizon
& Papahadjopoulos, 1988). HIV infectivity may not only
be inhibited by liposomes themselves but also by
encapsulated antisense oligodeoxynucleotides or reverse
transcriptase inhibitors which could enter the virus
interior via fusion. Hence, any virus-liposome fusion
product that does manage to inject its genome into the
cytoplasm of target cells would also introduce these
inhibitors. The encapsulation of proteases and nucleases
in liposomes may degrade the virus and its genome upon
fusion with the viral membrane and confer further
protection against HIV infection. The covalent coupling
of rsCD4 to the tiposomes may render the liposomes
highly specific for binding and fusion with HIV-1. These
studies are in progress in our laboratory.
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